GLP-1 Medications and Pregnancy: Safety and Discontinuation
What 2024–2025 research reveals about GLP-1 receptor agonist exposure during pregnancy, washout periods before conception, and clinical management of inadvertent first-trimester exposure.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on May 18, 2026
Our medical review process ensures clinical accuracy and patient safety.
With more than 12 million reproductive-age adults in the United States now exposed to GLP-1 receptor agonists for weight management or type 2 diabetes, an obvious but historically under-studied question has become urgent: what happens when a patient on semaglutide, tirzepatide, or liraglutide becomes pregnant?
Until 2024, the clinical answer was largely speculative. Pregnant women were excluded from every pivotal trial, and labels relied on animal teratology data showing fetal harm at high doses. The past 18 months have changed that. Three large prospective cohorts and a regulatory pooled analysis now provide the first credible human safety signals — and they have direct implications for how GLP-1 medications and pregnancy should be managed at the bedside.
Evidence: "Exposure to GLP1-RA in the first trimester was not associated with a risk of major birth defects when compared with diabetes (2.6% vs 2.3%; adjusted OR, 0.98, 95% CI 0.16 to 5.82) or to overweight/obese controls (2.6% vs 3.9%; adjusted OR 0.54, 0.11 to 2.75)." — Dao et al. BMJ Open. 2024. DOI
What GLP-1 Medications Do During Pregnancy
GLP-1 receptors are expressed in the placenta, the developing fetal pancreas, and several embryonic tissues. In rodent and primate studies, supratherapeutic doses of semaglutide and tirzepatide produced fetal growth restriction, skeletal anomalies, and increased embryonic loss — findings that drove the original FDA contraindication.
The translational relevance of those animal models has always been uncertain. Animal exposures were 5–60× the maximum human dose, and the toxicity correlated tightly with maternal weight loss rather than with direct receptor agonism. Human exposure during early pregnancy is now telling a much milder story.
Mechanistically Plausible Concerns
Three theoretical risks have anchored the conservative pregnancy guidance:
- Rapid maternal weight loss during organogenesis, which is independently associated with small-for-gestational-age infants
- Reduced caloric intake from suppressed appetite, potentially affecting fetal nutrient supply
- Delayed gastric emptying altering absorption of prenatal vitamins, folic acid, and oral medications including contraceptives
Each of these is real. None has produced a measurable congenital anomaly signal in the human data published so far.
Human Safety Data: The 2024–2025 Evidence
Four studies now anchor the human evidence base. Together they cover well over 1,200 first-trimester exposures — small by traditional pharmacoepidemiology standards, but the largest dataset ever assembled for these drugs in pregnancy.
Dao et al. (2024): Six-Country Teratology Cohort
The Dao study, published in BMJ Open, prospectively followed 168 GLP-1 RA–exposed pregnancies from six European Teratology Information Services and compared them against two reference groups: 156 pregnancies with diabetes and 163 with overweight/obesity. After adjustment for maternal age, BMI, and diabetes status, no signal emerged for major birth defects, spontaneous abortion, or preterm birth. Liraglutide accounted for most exposures, with smaller numbers of semaglutide, dulaglutide, and exenatide.
Parker et al. (2025): Pooled Regulatory Trials
A 2025 analysis published in Diabetes, Obesity and Metabolism pulled together every unplanned pregnancy reported in GLP-1 RA regulatory submissions to the FDA and EMA. The cohort included exposures to liraglutide, semaglutide, dulaglutide, exenatide, and tirzepatide.
Evidence: "Across regulatory clinical trials of GLP-1 receptor agonists, rates of congenital malformations and spontaneous abortion in inadvertently exposed pregnancies were broadly consistent with background population rates, and no consistent teratogenic pattern was identified." — Parker et al. Diabetes, Obesity and Metabolism. 2025. DOI
Kuitunen (2024): Register-Based Systematic Review
The Kuitunen review in Acta Paediatrica synthesized two large Nordic register cohorts encompassing 938 pregnancies. Pooled risk of congenital malformation after first-trimester GLP-1 RA exposure was not elevated relative to diabetic controls. Sample size remained insufficient to rule out rare anomalies, but the point estimates were reassuring.
Kolding et al. (2025): Danish Nationwide Cohort
A nationwide Danish study using prescription registries identified 235 semaglutide-exposed pregnancies and matched them to insulin-exposed and unexposed obese controls. Rates of major malformations were 3.4% in the semaglutide group versus 3.1% in the comparator groups — a non-significant difference. Preterm birth and large-for-gestational-age rates tracked closely with maternal BMI rather than with drug exposure.
| Study | Year | Exposed pregnancies | Major malformation rate | Comparator rate |
|---|---|---|---|---|
| Dao et al. | 2024 | 168 | 2.6% | 2.3%–3.9% |
| Kuitunen (pooled) | 2024 | 938 | Not elevated | Diabetic controls |
| Parker et al. | 2025 | 410+ | Background rate | Background |
| Kolding et al. | 2025 | 235 | 3.4% | 3.1% |
The convergence across independent cohorts using different methodologies is the strongest part of the signal. No single study is definitive; together they make a systemic teratogenic effect unlikely.
Discontinuation and Washout Periods
Reassuring safety data do not change the prescribing recommendation. GLP-1 receptor agonists remain contraindicated in pregnancy in every major regulatory jurisdiction. The clinically important question is when to stop the drug for patients planning conception.
Half-Life Drives the Washout
Pharmacokinetics — not theoretical fetal risk — determines the washout interval. A drug needs roughly five half-lives to fall below detectable plasma concentrations.
| Medication | Half-life | Recommended washout before conception |
|---|---|---|
| Liraglutide (Saxenda, Victoza) | ~13 hours | ≥3 days |
| Exenatide (Byetta) | ~2.4 hours | ≥1 day |
| Exenatide ER (Bydureon) | ~2 weeks | ≥10 weeks |
| Dulaglutide (Trulicity) | ~5 days | ≥25 days |
| Semaglutide (Ozempic, Wegovy, Rybelsus) | ~7 days | ≥35 days |
| Tirzepatide (Mounjaro, Zepbound) | ~5 days | ≥25–35 days |
Most fertility specialists go further than the pharmacokinetic minimum and recommend stopping GLP-1 medications 8–12 weeks before active conception attempts. The rationale is twofold: it allows weight to stabilize before pregnancy (avoiding active weight loss during organogenesis), and it provides a buffer for cycle regularity to normalize, particularly in patients with PCOS or prior anovulation. For more on planning around these medications, see our GLP-1 and fertility guide.
Contraception During Treatment
GLP-1 medications can blunt absorption of oral contraceptives, especially tirzepatide. The Zepbound label explicitly recommends that patients on oral contraceptives switch to a non-oral method or add a barrier method for four weeks after initiation and after each dose escalation. This guidance is not academic — it is one of the more common pathways to unplanned GLP-1 exposure in early pregnancy.
Inadvertent First-Trimester Exposure: Management
Despite the warnings, inadvertent exposure happens frequently. Restored fertility from weight loss, missed doses on oral contraceptives, or unrecognized pregnancy at the next scheduled injection are the typical scenarios. A structured response avoids both under-reaction and unnecessary alarm.
Immediate Steps
- Discontinue the GLP-1 RA at diagnosis of pregnancy. Continuing into the second trimester offers no metabolic benefit that outweighs the unstudied risk profile.
- Confirm gestational dating by ultrasound rather than relying on last menstrual period — cycle irregularity is common in this population.
- Transition glycemic management. For type 2 diabetes, insulin remains the gold standard during pregnancy. Metformin is a reasonable option in selected cases with appropriate counseling.
- Enhanced fetal monitoring is warranted, including a detailed anatomy scan at 18–22 weeks and serial growth assessments in the third trimester.
- Document and report. Most manufacturers maintain pregnancy registries; contributing data strengthens the evidence base for future patients.
Counseling Talking Points
- Available human data do not show an increased risk of major birth defects
- Sample sizes are still limited; rare anomalies cannot be excluded
- The pregnancy is not a candidate for elective termination on teratogenicity grounds based on current evidence
- Standard prenatal care plus the enhanced monitoring above is the appropriate path
Breastfeeding and the Postpartum Period
GLP-1 medications during breastfeeding remain an unanswered question. Semaglutide, tirzepatide, and liraglutide are large peptides unlikely to cross into milk in significant quantities, and would be partially degraded by infant gastric enzymes if they did. However, no human lactation studies have been completed, and all major labels recommend against use during breastfeeding.
For patients with strong metabolic indications, the decision becomes individualized. The American Diabetes Association's 2026 Standards of Care position metformin and insulin as preferred lactation-compatible options, with GLP-1 RAs reserved for cases where the maternal benefit clearly outweighs the theoretical infant exposure.
Evidence: "GLP-1 receptor agonists remain contraindicated in pregnancy and lactation pending additional safety data. Where pharmacotherapy is required during the periconception period, insulin and metformin remain the recommended options for glycemic management." — American Diabetes Association. Standards of Care in Diabetes. 2026. DOI
Resuming GLP-1 After Delivery
For patients who discontinued GLP-1 medications for pregnancy, postpartum resumption is generally appropriate once breastfeeding has concluded or if breastfeeding is not pursued. Weight regain in the year after delivery is a major driver of long-term obesity in women, and the metabolic environment of the postpartum period is a high-yield window for intervention. Patients planning subsequent pregnancies should expect the same washout discussion in advance of each conception attempt — guidance that aligns with the broader approach we outline in our weight regain after GLP-1 article.
Key Takeaways
- Four independent human cohorts (Dao 2024, Kuitunen 2024, Parker 2025, Kolding 2025) covering 1,200+ first-trimester exposures show no signal for increased major birth defects
- GLP-1 RAs remain contraindicated in pregnancy; the data is reassuring, not licensing
- Recommended washout before conception: ≥35 days for semaglutide, ≥25–35 days for tirzepatide, ≥3 days for liraglutide
- Many specialists extend the washout to 8–12 weeks to stabilize weight before organogenesis
- Tirzepatide blunts oral contraceptive absorption — non-oral or barrier contraception is required during initiation and dose escalation
- Inadvertent early exposure should prompt discontinuation, transition to insulin or metformin, and enhanced fetal monitoring — not termination counseling
- Breastfeeding data remain absent; insulin and metformin are the lactation-compatible alternatives
The science here is moving fast. Patients planning a pregnancy should make this conversation an explicit part of GLP-1 initiation rather than waiting until they are ready to conceive — the washout window matters, and so does the lead time on stabilizing weight, glycemia, and cycle regularity before conception.
References
- Dao K, Shechtman S, Weber-Schoendorfer C, et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open. 2024;14:e083550. DOI: 10.1136/bmjopen-2023-083550
- Parker CH, Slattery C, Brennan DJ, le Roux CW. Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials. Diabetes, Obesity and Metabolism. 2025;27(8):4102-4108. DOI: 10.1111/dom.16437
- Kuitunen I. Exposure to GLP-1 receptor agonists in early pregnancy did not increase the risk of congenital malformations. Acta Paediatrica. 2024. DOI: 10.1111/apa.17412
- Morton A, He J. Pregnancy outcomes following first trimester exposure to semaglutide. Obstetric Medicine. 2025. DOI: 10.1177/1753495X251346330
- Kolding L, et al. Pregnancy Outcomes After Semaglutide Exposure. Basic & Clinical Pharmacology & Toxicology. 2025. DOI: 10.1111/bcpt.70021
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 230: Obesity in Pregnancy. Obstetrics & Gynecology. 2021;137(6):e128-e144. PubMed: 34011890
- American Diabetes Association. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S321-S339. DOI: 10.2337/dc26-S015
Last updated: 2026-05-18 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.